Redeye leaves a research update following Klaria Pharma’s recently published Q2 2024 report. Overall, the report did not include any surprises and was in line with our estimates. While we are encouraged by the company’s short-term financial boost through the recent bridge loan instalment, we continue to believe that the company needs to secure its long-term financing and anticipate a capital raise. Following the recent market approval for sumatriptan, we see multiple further potential inflection points ahead that could elevate the share price.